ALK and non-small cell lung carcinoma: Determining whether the WEE1 rs3910384 G/G genotype can be used a biomarker for the option of platinum-gemcitabine regimen in NSCLC patients harboring no EGFR mutation and ALK rearrangement will better define this biomarker for the platinum-gemcitabine regimen and it is worth further validation in the future.